Figure 3.

Application of patient-derived FUTCs for pharmacological screening

(A) Schematic of FUTC-based drug sensitivity and resistance testing from clinical specimens.

(B) Viability assessment of patient-derived cells at days 0 and 3 after seeding in 384-well plates. Heatmap showing percentages of total cancer cells and Ki-67⁺ cancer cells normalized to total cancer cells in the tumor tissue.

(C) Heatmap representing percentage of cancer cells and KRAS mutation variant allele frequencies in patient-matched tumor tissues versus tumor-derived EpCAM⁺ cells.

(D) DSS (66 compounds) of tumor-derived EpCAM⁺ cells were clustered by using a complete linkage method, coupled with Euclidean distance measurement.

(E) Heatmap of Pearson’s correlation coefficient values between technical replicates of the same sample, or samples from different patients (left). Representative correlation plots of DSS values, comparing technical replicate screens of PLT68 (right).

(F) Correlation plot comparing the association between the percentage of cancer cells in the tumor tissue and Z′prime factors obtained from respective DSRT screens.